.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
A subsequent randomized trial refined the bedaquiline–pretomanid–linezolid approach by examining shorter and lower-intensity linezolid strategies in drug-resistant tuberculosis. The study included multiple BPaL-based treatment groups and showed that favorable outcomes remained high even when the linezolid component was reduced, while toxicity decreased with less linezolid exposure. Neuropathy and hematologic adverse effects were important limitations of the original regimen, so the findings have practical significance for treatment tolerability. For clinicians, the paper demonstrates how regimen optimization can be clinically as important as discovering a new drug. The aim is not simply to maximize antimicrobial intensity, but to maintain efficacy while minimizing preventable toxicity and treatment interruption. This is especially relevant in settings where follow-up capacity varies and patients may face long distances or financial barriers to repeated care. The findings strengthen a patient-centered approach to drug-resistant TB and fit the conference discussion of adherence as more than a behavioral issue: regimen length, adverse effects, monitoring, and access all shape whether patients can successfully complete treatment.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A subsequent randomized trial refined the bedaquiline–pretomanid–linezolid approach by examining shorter and lower-intensity linezolid strategies in drug-resistant tuberculosis. The study included multiple BPaL-based treatment groups and showed that favorable outcomes remained high even when the linezolid component was reduced, while toxicity decreased with less linezolid exposure. Neuropathy and hematologic adverse effects were important limitations of the original regimen, so the findings have practical significance for treatment tolerability. For clinicians, the paper demonstrates how regimen optimization can be clinically as important as discovering a new drug. The aim is not simply to maximize antimicrobial intensity, but to maintain efficacy while minimizing preventable toxicity and treatment interruption. This is especially relevant in settings where follow-up capacity varies and patients may face long distances or financial barriers to repeated care. The findings strengthen a patient-centered approach to drug-resistant TB and fit the conference discussion of adherence as more than a behavioral issue: regimen length, adverse effects, monitoring, and access all shape whether patients can successfully complete treatment.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
